tetano
Editor, Senior Moderator
World J Hepatol
. 2022 Dec 27;14(12):2012-2024.
doi: 10.4254/wjh.v14.i12.2012.
Liver chemistries in severe or non-severe cases of COVID-19: A systematic review and meta-analysis
Xuan Dong[SUP] 1 [/SUP], Dan-Yi Zeng[SUP] 1 [/SUP], Qing-Qing Xing[SUP] 1 [/SUP], Mei-Zhu Hong[SUP] 2 [/SUP], Jin-Shui Pan[SUP] 3 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease (COVID-19) patients exhibit different patterns of liver impairment, according to growing evidence.
Aim: In this study, we sought to provide a comprehensive analysis of liver test parameters in patients with severe and non-severe COVID-19.
Methods: We performed a meta-analysis of published liver manifestations and described the liver damage in COVID-19. We searched PubMed, Google Scholar, Embase, Cochrane Library, medRxiv, bioRxiv, and three Chinese electronic databases through April 18, 2020, in accordance with the Preferred Reporting Items for Meta-Analyses. We analyzed pooled data on liver chemistries stratified by COVID-19 severity using a fixed or random-effects model.
Results: A meta-analysis of 56 studies, including 11052 patients, found that the pooled mean alanine aminotransferase (ALT) in severe COVID-19 cases was 35.9 IU/L whereas in non-severe COVID-19 cases was 27.3 IU/L. Average aspartate aminotransferase (AST) levels were 44.3 IU/L in severe cases compared to 27.9 IU/L in non-severe cases. In addition, AST levels are often higher than ALT levels regardless of disease severity. The severe cases tended to have a higher gamma-glutamyltransferase level but a lower albumin level than the non-severe cases.
Conclusion: Severe COVID-19 was more likely to be associated with abnormal liver test results. Monitoring liver chemistry closely can help detect disease progression early.
Keywords: COVID-19; Liver chemistries; Meta-analysis; SARS-CoV-2; Severe; Systematic reviews and Meta-Analyses.
. 2022 Dec 27;14(12):2012-2024.
doi: 10.4254/wjh.v14.i12.2012.
Liver chemistries in severe or non-severe cases of COVID-19: A systematic review and meta-analysis
Xuan Dong[SUP] 1 [/SUP], Dan-Yi Zeng[SUP] 1 [/SUP], Qing-Qing Xing[SUP] 1 [/SUP], Mei-Zhu Hong[SUP] 2 [/SUP], Jin-Shui Pan[SUP] 3 [/SUP]
Affiliations
- PMID: 36618330
- PMCID: PMC9813841
- DOI: 10.4254/wjh.v14.i12.2012
Abstract
Background: Coronavirus disease (COVID-19) patients exhibit different patterns of liver impairment, according to growing evidence.
Aim: In this study, we sought to provide a comprehensive analysis of liver test parameters in patients with severe and non-severe COVID-19.
Methods: We performed a meta-analysis of published liver manifestations and described the liver damage in COVID-19. We searched PubMed, Google Scholar, Embase, Cochrane Library, medRxiv, bioRxiv, and three Chinese electronic databases through April 18, 2020, in accordance with the Preferred Reporting Items for Meta-Analyses. We analyzed pooled data on liver chemistries stratified by COVID-19 severity using a fixed or random-effects model.
Results: A meta-analysis of 56 studies, including 11052 patients, found that the pooled mean alanine aminotransferase (ALT) in severe COVID-19 cases was 35.9 IU/L whereas in non-severe COVID-19 cases was 27.3 IU/L. Average aspartate aminotransferase (AST) levels were 44.3 IU/L in severe cases compared to 27.9 IU/L in non-severe cases. In addition, AST levels are often higher than ALT levels regardless of disease severity. The severe cases tended to have a higher gamma-glutamyltransferase level but a lower albumin level than the non-severe cases.
Conclusion: Severe COVID-19 was more likely to be associated with abnormal liver test results. Monitoring liver chemistry closely can help detect disease progression early.
Keywords: COVID-19; Liver chemistries; Meta-analysis; SARS-CoV-2; Severe; Systematic reviews and Meta-Analyses.